Loading...
A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer.
Sivalingam, Vanitha McVey, R Gilmour, K Ali, S Roberts, C Renehan, Andrew G Kitchener, Henry C Crosbie, Emma J
Sivalingam, Vanitha
McVey, R
Gilmour, K
Ali, S
Roberts, C
Renehan, Andrew G
Kitchener, Henry C
Crosbie, Emma J
Citations
Altmetric:
Abstract
Metformin use is associated with reduced cancer risk in several observational studies of patients with type 2 diabetes. Results from preclinical studies in endometrial cancer show that metformin reduces cellular proliferation by inhibition of the PI3K-AKT-mTOR pathway. We tested the hypothesis that metformin would reduce cellular proliferation in vivo in atypical endometrial hyperplasia and endometrial endometrioid adenocarcinoma.
Description
Date
2015-02-26
Publisher
Collections
Keywords
Type
Article
Citation
A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. 2015, 385 Suppl 1:S90 Lancet